by McKesson Ventures | Aug 8, 2022 | Press Releases
On August 8, 2022, Augmedix reported its financial results for the three-month period that ended on June 30, 2022. Manny Krakaris, chief executive officer of Augmedix, noted that “we continued to see good momentum and are pleased with our strong start to 2022. We...
by McKesson Ventures | Aug 8, 2022 | Press Releases
Augmedix has announced a groundbreaking partnership with Adventist Health. The data-driven partnership aims to utilize Adventist’s experience as a nonprofit health system integrated into more than 80 communities in the western United States. The partnership was...
by McKesson Ventures | Jun 29, 2022 | Press Releases
Critical Path Institute (C-Path) and Replica Analytics, an Aetion company, have announced a partnership that uses synthetic data to help researchers more easily develop drugs to treat rare diseases. Replica Analytics will help generate synthetic datasets across rare...
by McKesson Ventures | Jun 29, 2022 | Media Coverage, Press Releases
Merck, known as MSD outside the U.S. and Canada, has announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. MDSS will support early-stage biomedical startups with direct...
by McKesson Ventures | Jun 17, 2022 | Press Releases
McKesson Ventures has signed the Parity.org ParityPledge® in Support of People of Color and in Support of Women. The ParityPledge simply asks that companies commit to interview and consider at least one qualified woman and person of color for every open role, VP and...
by McKesson Ventures | May 9, 2022 | Press Releases
OncoHealth announced today that Arsenal Capital Partners and McKesson Corporation have strategically invested in the company. The funding, which gives Arsenal a majority ownership stake in OncoHealth, will help the company continue developing its oncology-focused...
